Michael has played a key role in Organon’s global organization, helping to develop the business case, strategy as well as the stand-up of Organon as a spinoff company from Merck & Co since January 2019, supporting Organon’s CEO, Kevin Ali, as his Chief of Staff.
Having spent 20 years of his career within the pharmaceutical industry, 14 of those years at Merck/MSD in country, regional, global roles that have brought him to work in the U.S, Belgium, Finland, Switzerland and France before now coming back home to Canada. Prior to working on the spinoff, he successfully led MSD Finland (Merck’s subsidiary in Finland) as Managing Director, moving the company to the #1 multi-national pharmaceutical company in Finland during his tenure.
Michael holds an MBA from Columbia Business School in New York and a Bachelor of Science in Biochemistry from McGill University. Michael and his wife Charlotte have a 3-year-old son, James, and expecting a new addition to the family later this year.
Organon Canada, a subsidiary of Organon (NYSE: OGN), is a multi-national healthcare company formed through a spinoff from Merck. Organon is the only global healthcare company of its size focused on women’s health. We build upon our strong foundation of more than 60 medicines and other products across a range of areas including reproductive health, immunology, cardiovascular disease, dermatology, allergies and asthma.
With an international footprint that serves people in more than 140 markets, we bring these important therapies around the world. We believe the diversity of our business, and our people, provides a sustainable engine of growth so we can continue to invest in and advance new medicines and treatments. We understand that women are foundational to a healthier world and we especially focus on delivering solutions to women, which are so urgently needed.
For more information, visit www.organon.ca and connect with us on LinkedIn and Twitter.
All Sessions by Michael CasiaPrinter Friendly See Full Agenda
Day 1: Sep 14, 2022
CASE STUDY: ORGANON
Launching a New Pharmaceutical Company During the Pandemic
- Why Organon was created and the implications of launching a global healthcare company in today’s societal and post-pandemic context
- The need for a defined mission that aligns with the company’s values and unique business model
- The importance of building an internal culture and how to maintain this in a post-covid world
- Key learnings and considerations for the future
Day 2: Sep 15, 2022